Methods and compositions for treatment of excess nitric oxide or cyanide toxicity
Methods for treating disease states in a subject caused or exacerbated by the presence of excess nitric oxide (NO) or excess cyanide are provided. Methods for alleviating the symptoms of a disease state in a subject caused or exacerbated by the presence of excess nitric oxide (NO) or excess cyanide in the subject are also provided. Pharmaceutical compositions comprising cobinamide and a pharmaceutically acceptable carrier are also provided.
1. A method for delaying or inhibiting a disease state in a subject caused or exacerbated by the presence of excess cyanide in the subject in need thereof comprising: administering a pharmaceutically effective amount of cobinamide.
2. The method of claim 1 , wherein the subject is a cigarette smoker.
3. The method of claim 1 , wherein the excess cyanide is brought about by smoke inhalation, exposure to nitroprusside, or exposure to an industrial accident.
4. The method of claim 1 , wherein the excess cyanide is brought about by weapons of mass destruction.
5. The method of claim 1 , wherein the cobinamide is administered at a dose of 1 to 500 mg.
6. A method for alleviating the symptoms of a disease state in a subject caused or exacerbated by the presence of excess cyanide in the subject in need thereof comprising administering a pharmaceutically effective amount of cobinamide, wherein the subject is diagnosed as suffering from or at risk of developing a disease state caused or exacerbated by the presence of excess cyanide.
7. The method of claim 6 , wherein the subject is a cigarette smoker.
8. The method of claim 6 , wherein the excess cyanide is brought about by smoke inhalation, exposure to nitroprusside, or exposure to an industrial accident.
9. The method of claim 6 , wherein the excess cyanide is brought about by weapons of mass destruction.
10. The method of claim 6 , wherein the cobinamide is administered at a dose of 100 mg to 1 g.
11. A method for delaying or inhibiting cyanide toxicity in a subject in need thereof comprising administering a pharmaceutically effective amount of cobinamide to the subject.
12. The method of claim 11 , wherein the cobinamide is administered at a dose of 100 mg to 1 g.
13. The method of claim 1 , wherein cobinamide is administered at a dose of 100 mg to 1 g or 500 mg to 5 g.
14. The method of claim 1 , wherein the excess cyanide is brought about by smoke inhalation.
15. The method of claim 1 , wherein cobinamide is administered in a pharmaceutical composition with a pharmaceutically acceptable carrier.
16. The method of claim 1 , wherein cobinamide is administered intramuscularly.
17. The method of claim 1 , wherein cobinamide is administered intravenously, subcutaneously, or via inhalation.
18. The method of claim 1 , wherein cobinamide is administered with a pharmaceutically acceptable excipient.
19. The method of claim 6 , wherein cobinamide is administered at a dose of 1 to 500 mg or 500 mg to 5 g.
20. The method of claim 6 , wherein the excess cyanide is brought about by smoke inhalation.
21. The method of claim 6 , wherein cobinamide is administered in a pharmaceutical composition with a pharmaceutically acceptable carrier.
22. The method of claim 6 , wherein cobinamide is administered intramuscularly.
23. The method of claim 6 , wherein cobinamide is administered intravenously, subcutaneously, or via inhalation.
24. The method of claim 6 , wherein cobinamide is administered with a pharmaceutically acceptable excipient.
25. The method of claim 11 , wherein cobinamide is administered at a dose of 1 to 500 mg or 500 mg to 5 g.
26. The method of claim 11 , wherein the cyanide toxicity is brought about by smoke inhalation, exposure to nitroprusside, or exposure to an industrial accident.
27. The method of claim 11 , wherein cobinamide is administered in a pharmaceutical composition with a pharmaceutically acceptable carrier.
28. The method of claim 11 , wherein cobinamide is administered intramuscularly.
29. The method of claim 11 , wherein cobinamide is administered intravenously, subcutaneously, or via inhalation.
30. The method of claim 11 , wherein cobinamide is administered with a pharmaceutically acceptable excipient.